Literature DB >> 16833139

Accumulation and elimination of dietary arsenobetaine in two species of fish, Atlantic salmon (Salmo salar L.) and Atlantic cod (Gadus morhua L.).

Heidi Amlund1, Kevin A Francesconi, Claudette Bethune, Anne-Katrine Lundebye, Marc H G Berntssen.   

Abstract

Despite the fact that marine fish contain relatively high concentrations of the naturally occurring arsenic compound arsenobetaine, little is known about the disposition of arsenobetaine in fish. We investigated the accumulation, distribution, and elimination of dietary arsenobetaine in Atlantic salmon (Salmo salar L.) and Atlantic cod (Gadus morhua L.), with the focus on muscle, liver, and kidney tissues. The fish were exposed to dietary arsenobetaine (24.7 +/- 0.6 microg As/g feed) for three months, followed by a three-month depuration period. The two species showed marked differences in the accumulation and elimination of arsenobetaine. Total arsenic concentrations in Atlantic salmon increased significantly in muscle, liver, and kidney, whereas in Atlantic cod, a significant increase in total arsenic concentration was observed only in muscle. Elimination kinetics in muscle were distinct between the two species, with elimination half-lives from muscle tissue estimated at approximately 77 d in Atlantic cod and 37 d in Atlantic salmon, resulting in an absorption efficiency approximately twofold higher in Atlantic cod (15 +/- 1%) compared to that in Atlantic salmon (8 +/- 1%). The differences in arsenobetaine disposition studied in Atlantic salmon and Atlantic cod contribute to explain the differences in arsenic levels observed among marine fish.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16833139     DOI: 10.1897/05-107r1.1

Source DB:  PubMed          Journal:  Environ Toxicol Chem        ISSN: 0730-7268            Impact factor:   3.742


  1 in total

1.  Arsenic bioaccumulation in subarctic fishes of a mine-impacted bay on Great Slave Lake, Northwest Territories, Canada.

Authors:  John Chételat; Peter A Cott; Maikel Rosabal; Adam Houben; Christine McClelland; Elise Belle Rose; Marc Amyot
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.